RE: GEN1079 ready to dose?18 Jun 2026 14:37
Gemini says 'GEN1079 is an investigational, first-in-human antibody therapy currently being evaluated in a Phase 1 clinical trial for patients with advanced, inoperable solid tumors. Developed by Genmab (originally licensed from Scancell), it is designed to find and attack specific cancer cells